Fulgent Genetics Revenue Tops Estimates

Laboratory services and therapeutic development specialist Fulgent Genetics (NASDAQ:FLGT) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb. 28, the company reported adjusted EPS of $0.04, outstripping expectations of a $0.12 per-share loss. Q4 revenue climbed to $76.2 million, exceeding estimates of $74 million, marking an impressive annual growth of 8.1%.

Despite a GAAP earnings loss, the overall quarter showcased strength driven by a 14% increase in core revenue from its laboratory services segment.

Source: Fulgent Genetics. Note: Analyst consensus estimates for the quarter provided by FactSet. (YOY = Year over year.

Fulgent Genetics' Business Overview

Fulgent Genetics specializes in laboratory services and therapeutic development. Its laboratory division provides anatomic pathology and precision diagnostic testing through certified laboratories across the United States. Meanwhile, its therapeutic segment focuses on nano-drug delivery technology, with its lead candidate FID-007 targeting cancer treatments. Recently, the company has been focusing on transition strategies to ensure growth in core services and advancing its therapeutic projects, key factors necessary for future success.

The company experienced success in its laboratory services, shown by a 14% rise in core revenue year over year -- indicating the transition from pandemic-driven revenue to sustainable offerings. The business remains focused on therapeutic development advancements, especially with its FID-007 progressing in a Phase 2 trial. This initiative aligns with its goals of diversification and innovation.

Quarterly Achievements and Financial Highlights

Fulgent Genetics' fourth-quarter performance demonstrated success both financially and strategically. Revenue growth of 8.1% was supported by a considerable contract with Veterans Administration hospitals for hereditary cancer testing. Despite the success in top-line figures, the full-year GAAP loss of $42.7 million ($1.41 per share) reflects cost structures undergoing evaluation, transitioning COVID-19 revenue, and a warning of possible goodwill impairment.

The firm also reported progress in expanding its therapeutic offerings, emphasizing developments in FID-007 and FID-022. In the quarter, emphasis was placed on enhancing its core revenue, which was evident in laboratory services' 14% growth compared to the prior year. However, the cash generated from operations was limited to only $21.1 million for the year, highlighting the challenge of core activity cash generation.

Financial health remains a focal point, with the year ending on a robust $828.6 million cash reserve and marketable securities. Yet, the anticipated deeper GAAP loss in 2025 and the strained cash generation spotlight areas to watch for future periods, particularly in revenue diversification strategies.

Looking Ahead

For the upcoming year, management projects core revenue reaching approximately $310 million, predicting continued growth. Despite this optimistic forecast, an expected GAAP loss of $1.95 per share and a non-GAAP loss of $0.65 per share underscore potential financial hurdles. These projections suggest sizable ongoing investment requirements in core activities and strategic execution, posing critical monitoring areas for the coming year.

Investors should remain vigilant regarding the company's progress in leveraging strategic investments, particularly in its therapeutic segment and lab service capabilities. Emphasis on IP protection, regulatory compliance, and strategic acquisitions will be essential moving forward. Understanding how the firm navigates these avenues of growth will be critical in evaluating its future financial performance.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 870% — a market-crushing outperformance compared to 170% for the S&P 500.*

They just revealed what they believe are the 10 best stocks for investors to buy right now…

Learn more »

*Stock Advisor returns as of February 24, 2025

JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has positions in and recommends Fulgent Genetics. The Motley Fool has a disclosure policy.